AHA GUIDELINES Bundle (free trial)

Atrial Fibrillation 2023 Update

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/387790

Contents of this Issue

Navigation

Page 125 of 131

126 Management Table 29. Medical Cancer Therapy Associated With Increased Risk of AF (>1%) Cancer Therapy Frequency Reported in Clinical Trials and Observational Studies Comments Common: Incidence 1%–10% Frequent: >10% Anthracyclines Doxorubicin, epirubicin, idarubicin, mitoxantrone × AF may be a secondary result of anthracycline cardiotoxicity; studies in different populations demonstrate variable risk of AF Antimetabolites Clofarabine combined with cytarabine × × × 5 fluorouracil (5FU) × Cepecitabine Gemcitabine Alkylating agents Cyclophosphamide Melphalan + stem cell transplantation × ×* * Stem cell transplantation is associated with an increased risk of AF, and the risk may be higher with melphalan- associated regimens Immunomodulatory drugs × Given rates reported from patients with multiple myeloma, AF due to underlying cardiac AL amyloid may contribute Lenalidomide × Interleukin-2

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Atrial Fibrillation 2023 Update